ensartinib
Selected indexed studies
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. (JAMA Oncol, 2021) [PMID:34473194]
- Ensartinib. (, 2012) [PMID:40310967]
- Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial. (EClinicalMedicine, 2025) [PMID:40034576]
_Worker-drafted node — pending editorial review._
Connections
ensartinib is a side effect of
Sources
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. (2021) pubmed
- Ensartinib. (2012) pubmed
- Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial. (2025) pubmed
- [Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule]. (2020) pubmed
- Rutin attenuates ensartinib-induced hepatotoxicity by non-transcriptional regulation of TXNIP. (2024) pubmed
- [Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer]. (2022) pubmed
- Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC. (2019) pubmed
- Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor. (2021) pubmed
- Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials. (2025) pubmed
- Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer. (2023) pubmed